Novartis Ag

Novartis Pharma Gmbh

Achim Schlapbach

Pascal Furet

Robert Mah

Vito Guagnano

Andrea Vaupel

Keiichi Masuya

Philipp Holzer

Joerg Kallen

Stefan Stutz

Marina Tintelnot-Blomley

Oliver Simic

Jean Quancard

Carole Pissot Soldermann

Thomas Zoller

Birgit Bollbuck

Giorgio Caravatti

Lv Liao

Philipp Janser

Simona Cotesta

Patricia Imbach

Timothy M Ramsey

Liang Mao

Richard Heng

Guido Koch

Lászlo Révész

Dieter Scholz

Jorg Eder

L&aacute;szlo R&eacute;v&eacute;sz

Rudolf Wälchli

René Hersperger

Jörg Eder

Laszio Revesz

Alastair DenholmMritain

Rudolf Wálchi

Alastair Novartis Horsham Research Ctre Denholm

Timothy Michael Ramsey

The present invention describes new pyrazolo-pyrimidine derivatives according to Formula (I) which are generally interacting with MALT1 proteolytic and/or autoproteolytic activity, and in particular which may inhibit said activity. The present invention further describes the synthesis of said new pyrazolo-pyrimidine derivatives, their use as a medicament, especially by interacting with MALT1 proteolytic and/or autoproteolytic activity.

Pyrazolo pyrimidine derivatives and their use as MALT1 inhbitors

The present invention describes new pyrazolo-pyrimidine derivatives which are generally interacting with MALT1 proteolytic and/or autoproteolytic activity, and in particular which may inhibit said activity. The present invention further describes the synthesis of said new pyrazolo-pyrimidine derivatives, their use as a medicament, especially by interacting with MALT1 proteolytic and/or autoproteolytic activity.

Pyrazolo pyrimidine derivatives and their use as MALT1 inhibitors

The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds. 

Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction

The invention relates to compounds of formula (I): (I) as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of as MDM2 and/or MDM4, and combinations comprising such compounds. 

Substituted purinone compounds

The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.

Pyrrolopyrrolidinone compounds

The invention relates to compounds of formula (I) as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds. 

Pyrazolopyrrolidine compounds

Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases

The present invention describes tetracyclic compounds of formula (IA) or (IB), wherein the symbols R, X, A, Y, R2, R3 and D are as defined in the specification, their use in the treatment of certain diseases, e.g. depending on MK-2 or TNF activity, and ways of manufacturing them.

Tetracyclic lactame derivatives

The invention relates to phenyl-[4-(3-phenyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives and to processes for the preparation thereof, to pharmaceutical compositions comprising such derivatives and to the use of such derivatives&#x2014;alone or in combination with one or more other pharmaceutically active compounds&#x2014;for the preparation of pharmaceutical compositions for the treatment especially of a proliferative disease, such as a tumor.

Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl)-amine derivatives

A compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the symbols have meaning as defined, which are antagonists of CCR-1 and which find use pharmaceutically for treatment of diseases and conditions in which CCR-1 is implicated, e.g. inflammatory diseases. 

1-(4-Benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives

A compound of formula I or a pharmaceutically acceptable salt, ester or prodrug thereof wherein the variables have the meanings as defined in the specification. Further disclosed are a method of inhibiting IKK activity using a compound of formula I, a method of inhibiting production of TNF using a compound of formula I, a compound of formula I for use as a pharmaceutical, a pharmaceutical composition comprising a compound of formula I, and use of a compound of formula I in the manufacture of a medicament for use as an immunosuppressant or anti-inflammatory agent. 

2-aminopyrimidine derivatives and their medical use

Substituted azoles

Growing community of inventors

Lorrach, Germany

Achim Schlapbach